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Mesencephalic dopaminergic neurons were suggested to be a critical physiopathology
substrate for addiction disorders. Among neuroadaptive processes to addictive drugs,
structural plasticity has attracted attention.While structural plasticity occurs at both pre- and
post-synaptic levels in the mesolimbic dopaminergic system, the present review focuses
only on dopaminergic neurons. Exposures to addictive drugs determine two opposite
structural responses, hypothrophic plasticity produced by opioids and cannabinoids (in
particular during the early withdrawal phase) and hypertrophic plasticity, mostly driven
by psychostimulants and nicotine. In vitro and in vivo studies identiﬁed BDNF and
extracellular dopamine as two critical factors in determining structural plasticity, the
two molecules sharing similar intracellular pathways involved in cell soma and dendrite
growth, the MEK-ERK1/2 and the PI3K-Akt-mTOR, via preferential activation of TrkB and
dopamine D3 receptors, respectively. At present information regarding speciﬁc structural
changes associated to the various stages of the addiction cycle is incomplete. Encouraging
neuroimaging data in humans indirectly support the preclinical evidence of hypotrophic and
hypertrophic effects, suggesting a possible differential engagement of dopamine neurons
in parallel and partially converging circuits controlling motivation, stress, and emotions.
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INTRODUCTION
Structural plasticity in neurons can be deﬁned as a series of mea-
surable changes in the morphologically deﬁned components of
the neuron, i.e., numbers, size, and composition of soma, den-
drites, axons, and synapses, occurring over time and in response
to changes in the cell environment. Structural plasticity can also be
seen as one aspect of neuroadaptation, a general process present
in neurons of speciﬁc neural circuits when responding to repeated
physiologic stimuli, pathologic agents, or effective doses of phar-
macologic substance, including addictive drugs (Ikemoto and
Bonci, 2014). These stimuli act by engaging molecular mecha-
nisms that are critical for cell growth and survival, their impact on
the cell morphology being deﬁned by the stimulus intensity and
by genetic and epigenetic predisposing factors that constitute the
neuroadaptive potential of the cells.
Since 1990s neuroadaptation and plasticity have been recog-
nized tobe relevant in addictiondisorders characterizedby chronic
misuse of neuroactive substances (Koob, 1992; Nestler, 1992; Di
Chiara, 1995; Everitt et al., 2001). In mammals, pharmacologic
agents characterized by their addictive properties, for example psy-
chostimulants (e.g., cocaine, amphetamines), opioids (e.g., heroin
and morphine), nicotine, cannabinoids, and alcohol, were found
to engage dopaminergic neurons of themesocorticolimbic contin-
gent located in the ventral tegmental area (VTA) (Koob, 1992; Di
Chiara, 1995; Koob and Le Moal, 2005; Chen et al., 2010). These
neurons produce dopamine (DA) as principal neurotransmitter,
project to cortical and limbic brain structures and are involved
in regulation of motivation, reward, motor response selection,
mood, and arousal. While a large body of experimental ﬁndings
supports the role for dopaminergic neurotransmission in medi-
ating the addictive properties of these drugs (Koob, 1992; Di
Chiara, 1995; Koob and Le Moal, 2005; Kalivas and O’Brien, 2008;
Chen et al., 2010), less research was dedicated to the structural
changes occurring during exposure to addictive drugs or follow-
ing their withdrawal. The initial interest on structural plasticity
was focused on glutamatergic and GABAergic neurons of nucleus
accumbens and prefrontal cortex, i.e., on neurons located in ter-
minal ﬁelds of the mesencephalic dopaminergic system (Robinson
and Kolb, 1997, 2004; Russo et al., 2010) rather than on their
presynaptic side. In dopaminergic neurons structural plasticity
was indirectly inferred on the basis of changes in the expres-
sion of “marker” proteins though to be involved in structural
changes, such as axonal neuroﬁlaments (Nestler, 1992), a phe-
nomenon only later conﬁrmed using morphological techniques
(Sklair-Tavron et al., 1996). In fact, by deﬁnition, structural plas-
ticity requires morphologic evidence. Dopaminergic neurons are
generally identiﬁed by immunocytochemistry or immunoﬂuores-
cence with selective antibodies that recognize tyrosine hydroxylase
(TH)or dopamine transporter (DAT;Köhler andGoldstein,1984).
When applied to the post-mortem study in mammalian brains,
TH immunocytochemistry allows reliable estimate of soma size
and neuron counts in substantia nigra (SN, also identiﬁed as A9)
and VTA (also identiﬁed as A10). Conversely, a proper analysis
of the dendrite length and branching is not possible, due to the
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complex overlapping of the dendritic arborizations of adjacent
dopaminergic neurons. Visualization of dendrites and dendritic
spines of a single neuron requires different approaches, such as the
classical Golgi-Cox staining (Juraska et al., 1977) associated with
immunohistochemistry (Spiga et al., 2011) intracellular injection
with Lucifer Yellow via micropipettes (Sklair-Tavron et al., 1996)
or diolistic gene gun delivery of ﬂuorescent dyes (Shen et al.,
2008). Dopaminergic neurons can be studied in vitro using pri-
mary cell cultures from the ventral mesencephalon of rodent
embryos or newborns (Shimoda et al., 1992; Collo et al., 2008).
The in vitro approach allows the simultaneous evaluation of soma
size, dendritic arborization, dendritic spines, neurochemistry, and
intracellularmolecular signaling due to their sparse distribution in
the culture dish and their standardized control conditions (Collo
et al., 2008, 2012).
In this article we summarize the evidence of structural plastic-
ity occurring in mesencephalic dopaminergic neurons following
exposure to addictive drugs, focusing on soma, and dendritic
arborization rather than synapses and addressing the key molecu-
lar intracellular signaling involved.
STRUCTURAL PLASTICITY IN DOPAMINERGIC NEURONS AS
CELLULAR NEUROADAPTATION: OPPOSITE EFFECTS OF
OPIOIDS AND PSYCHOSTIMULANTS
Structural plasticity includes hyperplastic and hypoplastic phe-
nomena, i.e., the increase or decrease of number and size of
morphologically deﬁned components of the neuron. In the brain
reward circuit, drugs of addiction produce both hyperplastic and
hypoplastic phenomena, the former generally associated to psy-
chostimulants, the latter to the use of opioids (for review see
Russo et al., 2009, 2010). Since chronic exposure to both opioids
and psychostimulants produces behavioral sensitization, compul-
sive drug taking, and relapse after extinction, at the time of their
initial discovery these changes appeared somewhat contradictory,
casting some doubts about the relevance of structural plastic-
ity in addictive behavior. Recent ﬁndings regarding the role of
withdrawal state (Spiga et al., 2010; Mazei-Robison et al., 2011),
region-speciﬁc changes of synaptic spines (Russo et al., 2010) and
differential regulation of endogenous neurotrophins, in particular
brain derived neurotropic factors (BDNF) (Russo et al., 2009; Koo
et al., 2012), have been advocated as key factors in disentangling
this paradox; some possible explanations will be reviewed later in
this article.
Chronic exposures to opioids reduce soma size and den-
drites of the dopaminergic neurons located in the VTA of adult
rodents without reducing the number of neurons (Sklair-Tavron
et al., 1996; Spiga et al., 2003; Russo et al., 2007). Opioid-induced
hypotrophic effects on soma were observed following either pas-
sive dosing or self-administration of heroin or morphine and
persist for several weeks during withdrawal. Functionally, chronic
exposure to opioids is known to increase VTA neural ﬁring while
reduction is observed during withdrawal (Diana et al., 1995; Koo
et al., 2012).
Reduced soma size and neural ﬁring were also observed during
withdrawal fromcannabinoids in rodents (Diana et al., 1998; Spiga
et al., 2010). These effects are partially determined by endoge-
nous opioids since acute morphine attenuates the behavioral
cannabinoidwithdrawal syndrome inmice (Lichtman et al., 2001).
Interestingly, chronic exposure to cannabinoids per se does not
produce change of soma sizes of VTA dopaminergic neurons. Lack
of change in the soma size was also recently showed in rats trained
to chronically self-administer cocaine, nicotine, and alcohol when
sacriﬁced in presence of drugs (Mazei-Robison et al., 2011). These
data do not rule out the possibility of changes during withdrawal
or crash after drug taking “binges,” both conditions associated
to a functional hypodopaminergic state (Weiss et al., 1992; Melis
et al., 2005; Zhang et al., 2012); so far structural effects were not
studied.
Cocaine and amphetamine exposures in vivo increase den-
drite arborization and spines in VTA (Mueller et al., 2006; Sarti
et al., 2007). In vitro studies on primary cultures of mesen-
cephalic neurons from mouse embryos corroborate this evidence.
Dose-dependent increases of soma size, maximal dendrite length,
and number of primary dendrites were observed (Collo et al.,
2008, 2012). Interestingly, also nicotine was shown to increase
structural plasticity of dopaminergic neurons in vitro, effect
blocked by mecamylamine and dihydro-β-erythroidine but not
methyllycaconitine, suggesting the involvement of α4β2 nico-
tinic receptor (nAChR; (Collo et al., 2013). These nicotinic
hetero-receptors expressed in dopaminergic neurons control DA
release and are critical for the reinforcing effects of nicotine
in vivo (Picciotto et al., 1998). Consistently, dopaminergic neu-
rons from the mesencephalon of α4 nAChR-subunit knock out
(KO) mice did not show nicotine-induced plasticity (Collo et al.,
2013).
Prenatal exposure to either cocaine or nicotine during the last
gestational phase (E17-21) was associated with signiﬁcant increase
of soma size of dopaminergic neurons in newborns and young
mice (Collo et al., 2012, 2013). Prenatal exposures to cocaine and
amphetamines produce long-term changes in the behavior and
neurochemistry of the mesencephalic dopaminergic system of off-
spring assessed as adults (Crozatier et al., 2003; Lloyd et al., 2013),
suggesting a possible association between dopaminergic structural
plasticity and liability to develop addiction.
CRITICAL ROLE OF THE BDNF-TrkB SIGNALING IN
DETERMINING STRUCTURAL PLASTICITY OF
DOPAMINERGIC NEURONS EXPOSED TO ADDICTIVE DRUGS
Neurotrophic factors that bind to the tropomyosin-related kinase
B (TrkB) receptor were shown to be of importance in the devel-
opment of the central nervous system (CNS) and in shaping
neuronal morphology of dopamine neurons and other brain
circuits (for a review see Ohira and Hayashi, 2009). In par-
ticular, BDNF-TrkB signaling has been extensively studied as
critical mediator of the structural changes produced by addic-
tive drugs (Russo et al., 2009; Koo et al., 2012). Mesencephalic
dopaminergic neurons signiﬁcantly express BDNF since prena-
tal time (Baquet et al., 2005). Still present in adult life, BDNF
expression can be transiently increased by psychostimulants in
VTA dopaminergic neurons (Graham et al., 2007). These increases
consolidate and persist over time during abstinence (Pu et al.,
2006) and during extinction of drug self-administration and in
craving incubation paradigms (Grimm et al., 2003). Infusion of
BDNF inVTA induces long-lasting potentiation of cocaine seeking
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during abstinence (Lu et al., 2004), while BDNF immunoneu-
tralization attenuates the cocaine addictive behavioral effects
(Graham et al., 2007). To our knowledge, direct evidence of
structural changes in dopaminergic neurons during withdrawal,
abstinence and incubation with psychostimulants is lacking in
literature. However, in consideration of the well-known BDNF
neurotrophic properties on dendrites and soma size, it is possible
to speculate that some structural plasticity could occur. Inter-
estingly, GDNF, another neurotrophic factor, increases in VTA
during cocaine withdrawal and mediates incubation of cocaine
craving (Lu et al., 2009), further supporting possible structural
effects.
Almost opposite effects were observed with opioids: mor-
phine reduces BDNF expression in VTA neurons; low BDNF
levels were associated with reduced soma size, and local infu-
sion with BDNF normalizes soma size (Sklair-Tavron et al., 1996;
Russo et al., 2009). Recent studies using conditional KO mice
and optogenetic technology showed that morphine-induced low
levels of BDNF in the VTA are associated to hypersensitization
of VTA dopaminergic neurons to morphine, whose adminis-
tration increases ﬁring and DA release, producing conditioned
place preference (Koo et al., 2012). Conversely, acute withdrawal
and abstinence are associated with increased BDNF expression
and TrkB-mediated plasticity changes that are essentials for neg-
ative reinforcing effects of morphine withdrawal (Vargas-Perez
et al., 2014). Interestingly, the opioid effects on DA release are
indirect, mediated by GABAergic inhibitory neurons under gluta-
matergic control (Bonci and Williams, 1997; Vargas-Perez et al.,
2009; Jalabert et al., 2011), suggesting a role also for these
neurotransmitters.
The main intracellular pathways activated by BDNF-TrkB
signaling are the MEK-ERK, the PI3K-Akt-mTORC1, the PLCy-
DAG-PKC/Ca2+, and NFkB pathways, all involved in cell survival
and growth (Kumar et al., 2005; Russo et al., 2009). These path-
ways are not only activated by BDNF but also by G-protein
coupled receptors (e.g., Girault et al., 2007). Recent evidence
indicates that cocaine and nicotine activate both MEK-ERK
and Akt-mTORC1 pathways in primary cultures of dopamin-
ergic neurons (Collo et al., 2012, 2013). Phosphorylation in
these two pathways was found critical for structural plastic-
ity since pretreatments with selective inhibitors for ERK, PI3K,
and mTORC1 block the increase of soma size and dendritic
arborization produced by psychostimolants and nicotine (Collo
et al., 2013). Conversely, morphine exposure was associated with
reduction in Akt levels and phosphorylation, attenuating mTOR-
dependent phosphorylation (Russo et al., 2007; Mazei-Robison
et al., 2011). The central role of the PI3K-Akt-mTOR path-
way in determining soma size of mesencephalic dopaminergic
neurons is exempliﬁed by the phosphatase and tensin homolog
(PTEN) KO mice. PTEN is a negative regulator of PI3K whose
null mutation leads to a constitutive preferential state of activa-
tion of Akt-mTORC1 pathway; the result is a massive increase
in soma size of dopaminergic neurons already visible in new-
borns, that persists in adult mice (Diaz-Ruiz et al., 2009). Other
mechanisms affecting dendrite and soma size include the mod-
ulation of Ca2+ levels and the cAMP production, the latter
not operated by BDNF. A large body of evidence indicates that
Ca2+-dependent AMPA and NMDA glutamate receptors reg-
ulate dendrite growth in pyramidal neurons and interneurons
(Hamad et al., 2011). Indopaminergic neuronsNMDA-dependent
axonal growth was described as related to CaMKII phospho-
rylation (Schmitz et al., 2009), while preliminary in vitro data
indicate a critical role for AMPA receptors. In GABAergic neurons
located in the VTA, chronic activation of the cAMP-PKA-CREB
was associated with reduced ﬁring and soma size in dopaminergic
neurons during morphine withdrawal (Bonci and Williams, 1997;
Koo et al., 2012), suggesting an indirect involvement in structural
plasticity.
Interestingly, structural changes of soma size and dendritic
arborization of dopaminergic neurons are not speciﬁc of addic-
tive drugs. In a recent article a reduction of soma size in the
VTA was observed in male rats after single and repeated mat-
ing episodes (Pitchers et al., 2014). Naloxone treatment reversed
soma size reduction and attenuated the longer-term expression
of experience-induced facilitation of sexual behavior without
affecting its rewarding properties. In another study, an increase
of the number, size, and dendritic spines of mesencephalic
dopaminergic neurons was associated to exercise and intense
motor behavior in rats exposed to moderate dose of dopamin-
ergic neurotoxins (Real et al., 2013), supporting a role for neu-
rotrophic BDNF-TrkB signaling in behaviorally induced structural
plasticity.
DOPAMINE AS NEUROTROPHIC FACTOR: ROLE OF D3
RECEPTOR SIGNALING IN STRUCTURAL PLASTICITY OF
DOPAMINERGIC NEURONS
In addition to its role as a neurotransmitter, DA can act as
neurotrophic factor. When released in the extracellular space,
DA binds to postsynaptic receptors, producing structural plas-
ticity: for example DA increases TrkB phosphorylation via D1
receptor (Iwakura et al., 2008). DA also binds to presynaptic
D3, D2S, and D5 receptors located on dopaminergic neurons
(Zhang and Sulzer, 2012). Functional studies in mutant mice
indicate that D2 and D3 receptors are complementary in reg-
ulating phasic and tonic dopamine release from dopaminergic
nerve terminals in caudate and nucleus accumbens (Le Foll et al.,
2005b; Maina and Mathews, 2010). The intracellular pathways
activated by the presynaptic DA receptors and related to struc-
tural plasticity are only partially understood, being the majority of
studies performed in non-dopaminergic cells. Converging ﬁnd-
ings indicated a primary role for D3 receptors in dopaminergic
structural plasticity via phosphorylation of MEK-ERK1/2 and
PI3K-Akt-mTORC1 pathways (Cussac et al., 1999; Beom et al.,
2004; Collo et al., 2012, 2013). Conversely, D2s receptors inhibit
MEK-ERK1/2 pathway and are negatively coupled with adenylate-
cyclase (Van-Ham et al., 2007). PLCy activation and β-arrestin
non-canonical pathways were described for the D2L splice vari-
ant present on postsynaptic neurons (Del’guidice et al., 2011).
Finally, less data are available on D5 receptor, whose role has been
related to functional plasticity (Schilström et al., 2006; Argilli et al.,
2008).
Direct evidence linking D3 receptors and structural plasticity
was recently obtained in primary cultures of dopaminergic neu-
rons from mouse embryos. Repeated exposure with low doses
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of D3-preferential agonists, such as quinpirole or 7OH-DPAT,
increased soma size and the number and length of primary den-
drites (Collo et al., 2008). These effects were also produced by
drugs of addiction such as cocaine, amphetamine, nicotine, and
ketamine, all known to increase extracellular levels of DA in the
VTA. Pretreatments with DA D3 selective antagonist SB277011-
A and the non-selective D2/D3 antagonist sulpiride resulted in
a blockade of dendrite outgrowth and soma size (Collo et al.,
2008, 2012). No structural plasticity was observed when treat-
ments with psychostimulants or nicotine were performed in cell
cultures from the mesencephalon of D3 KO mice (Collo et al.,
2008, 2012, 2013). When nicotine was repeatedly administered
to pregnant D3 KO mice during the last gestational phase, no
effect was observed on the soma size of VTA neurons of new-
borns. Recent evidence suggests that D3 receptors work in concert
with BDNF-TrkB signaling. In vivo experiment showed that D3
receptor expression depends on the levels of BDNF (Guillin et al.,
2003) and that cocaine exposure increases the synthesis of both
BDNF and D3 receptors (Le Foll et al., 2005a), while morphine
increases the expression of D3 receptors only (Spangler et al.,
2003), marking a difference between the two addictive drugs
(Figure 1).
HUMAN EVIDENCE OF ADDICTIVE DRUG INDUCED
STRUCTURAL PLASTICITY
No direct human evidence of structural plasticity induced by
addictive drugs in dopaminergic neurons is currently available.
Post-mortem studies in cocaine users revealed a 16% reduction
of melanized dopaminergic neurons with no reported change
of soma size (Little et al., 2009), while a reduction of TH levels
in dopaminergic terminals of the striatum was found in heroin
addicts (Kish et al., 2001).
In vivo neuroimaging studies, which lack cellular resolu-
tion, showed reduced 6-FDOPA uptake in the dopaminergic
terminals of the striatum of cocaine addicts during 10–30 days
of abstinence (Wu et al., 1997). Interestingly, another marker
of dopaminergic terminals in striatum, i.e., DAT levels, was
found reduced in methamphetamine addicts (Chang et al., 2007)
and in tobacco and marijuana smokers (Leroy et al., 2012).
Extracellular DA release estimated using the 11C-raclopride
displacement techniques indicated a lower DA tone in ven-
tral striatum of cocaine (Martinez et al., 2009) and marijuana
users (Volkow et al., 2014), the latter correlated with enhanced
stress reactivity and irritability, conﬁrming a hypodopamin-
ergic state. Structural MRI showed a volumetric increase in
the left nucleus accumbens in marijuana users (Gilman et al.,
2014), enlarged striatum in methamphetamine users (Chang et al.,
2007) and reduction in nucleus accumbens, anterior cingulated
and orbitofrontal cortex in children exposed in utero to opi-
oids (Walhovd et al., 2007), all ﬁndings in line with preclinical
observations.
CONCLUSION AND FUTURE RESEARCH
Addictive drugs induce structural plasticity in dopaminergic neu-
rons. While a complete picture of structural changes associated to
the different stages of the addiction cycle and its translational value
in human is still lacking, differences among the main addictive
drugs in producing either hypotrophic or hypertrophic response
stand out, driven by the respective down or up regulations of
BDNFandextracellular dopamine levels. These effects canbemore
FIGURE 1 | Schematic representation of relevant intracellular
pathways of BDNF and dopamine dependent structural plasticity in
dopaminergic neurons. TrkB, tropomyosin-related kinase B; Src,
proto-oncogene tyrosine protein kinase; MEK, mitogen-activated protein
kinase; ERK1/2, extracellular signal-regulated kinase; D3R, dopamine D3
receptor; Giβγ, G protein; PI3K, phosphatidylinositol 3-kinase; Akt, serine
threonine kinase or protein kinase B; mTORC1, mammalian target of
rapamycin complex 1; p70S6K, p70 ribosomal S6 protein kinase;
PD98059, MEK inhibitor; LY294002, PI3K inhibitor; rapamycin, mTORC1
inhibitor; SB277011A, selective D3R inhibitor.
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conspicuous during neural development, as shown in offspring
following in utero exposure or in vitro using embryo-derived cell
cultures. Overall, structural changes appear to be related to some
differences in targeting of reward and stress circuits that work in
parallel to control motivation (Koob, 2013; Ikemoto and Bonci,
2014). These long term structural changes can be seen as sub-
strates of “memory” traces (Nestler, 2013) that would eventually
constitute a liability for drug taking relapse.
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